NCT03006393View on ClinicalTrials.gov

Dynamics of Inflammation and Its Blockade on Motivational Circuitry in Depression

PHASE4CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

August 31, 2016

Primary Completion Date

September 26, 2020

Study Completion Date

September 26, 2020

Conditions
Depression
Interventions
DRUG

Infliximab

One infusion of Infliximab (Remicade) will be administered intravenously (IV) at 5 mg/kg body weight over a two hour period.

OTHER

Placebo

One infusion of placebo treatment will be administered intravenously (IV) over a two hour period.

Trial Locations (1)

30322

Emory University, Atlanta

All Listed Sponsors
collaborator

National Institute of Mental Health (NIMH)

NIH

lead

Emory University

OTHER

NCT03006393 - Dynamics of Inflammation and Its Blockade on Motivational Circuitry in Depression | Biotech Hunter | Biotech Hunter